All In Biotech

Drug Trial Radar · NCT07274137

A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of MDR-001 Administered Orally Over 52 Weeks in Participants With Overweight or Obesity (MOBILE)

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 738 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

738

Planned (sponsor's estimate)

Start

Feb 2026

Primary completion

Jun 2027

Study completion Jul 2027

Sponsor

Lead sponsor
MindRank AI LtdIndustry
Sponsor type
Industry
First posted
Dec 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study to evaluate the efficacy and safety of the oral small molecule MDR-001 Tablets over 52 weeks as an adjunct to a lifestyle intervention in participants with overweight or obesity.The goal of this clinical trial is to determine whether the oral drug MDR-001 can improve weight management in adult participants with overweight or obesity.

Conditions

  • Overweight or Obesity

Interventions

  • MDR-001Drug

    Participants will Receive Small Molecule MDR-001 Tablets Administered Orally

  • PlaceboDrug

    Participants will Receive Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change from baseline in body weight (%) at Week 52Time frame: baseline,Week 52
  2. Percentage (%) of participants who achieve≥5% body weight reduction from baseline at Week 52Time frame: baseline,Week 52

Locations

45 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, China

  • The Second Hospital of Jilin University

    Changchun, China

  • The First People's Hospital of Changde City

    Changde, China

  • People's Hospital of Hunan Province

    Changsha, China

  • The Fourth Hospital of Changsha

    Changsha, China

  • The Third People's Hospital of Datong

    Datong, China

  • Dongyang People's Hospital

    Dongyang, China

  • Ganzhou People's Hospital

    Ganzhou, China

  • The Second Hospital of Anhui Medical University

    Hefei, China

  • The SecondPeople's Hospital of Hefei

    Hefei, China

  • Huizhou Central People's Hospital

    Huizhou, China

  • Huizhou Third People's Hospital

    Huizhou, China

  • Huzhou Central Hospital

    Huzhou, China

  • Central Hospital Affiliated To Shangdong First Medical University

    Jinan, China

  • Central Hospital of Jin zhou

    Jinzhou, China

  • Jingzhou Hospital Affiliated to Yangtze University

    Jinzhou, China

  • The Third Affiliated Hospital of Jinzhou Medical University

    Jinzhou, China

  • JiuJiang No.1 people's Hospital

    Jiujiang, China

  • Lianyungang Hospital of TCM

    Lianyungang, China

  • Liaocheng People's Hospital

    Liaocheng, China

  • Loudi Central Hospital

    Loudi, China

  • The First Affiliated Hospital of Ningbo University

    Ningbo, China

  • Pingxiang People's Hospital

    Pingxiang, China

  • Sanya Central Hospital (Hainan Third People's Hospital)

    Sanya, China

  • Shenyang Fifth People Hospital

    Shenyang, China

  • Shenyang Sixth People's Hospital

    Shenyang, China

  • The People's Hospital of liaoning Province

    Shenyang, China

  • The Second Hospital of Hebei Medical University

    Shijia Zhuang, China

  • Siping Central People's Hospital

    Siping, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, China

  • First Hospital of Shanxi Medical University

    Taiyuan, China

  • Shanxi Bethune Hospital

    Taiyuan, China

  • Taizhou Hospital of Zhejiang province

    Taizhou, China

  • Wuhan Third Hospital•Tongren Hospital of Wuhan University

    Wuhan, China

  • Xuancheng People's Hospital

    Xuancheng, China

  • Yichang Central People's Hospital

    Yibin, China

  • Yichang Central People's Hospital

    Yichang, China

  • Yueyang Central Hospital

    Yueyang, China

  • Yueyang People's Hospital

    Yueyang, China

  • The Second Affiliated Hospital of ZhengzhouUniversity

    Zhengzhou, China

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.